Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
Summary not available.
Summary not available.
Summary not available.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will announce its first quarter 2023 financial results on May 8, 2023. The results will be shared before market opening, followed by a conference call at 8:30 a.m. ET, hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey. Investors can participate by calling 800-245-3047 or via a live webcast on the company’s website. A replay of the call will be available shortly after and last for two weeks. ANI Pharmaceuticals focuses on providing high-quality branded and generic pharmaceuticals, particularly for conditions with significant unmet medical needs. The company aims for sustainable growth through its Purified Cortrophin® Gel franchise and enhancing its generics portfolio.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 12:00 p.m. ET in New York City. The event will be available via webcast.
Investors can access the live presentation by clicking here. The recorded version will be available on demand starting May 3, 2023, at 7:00 a.m. ET for 90 days.
ANI Pharmaceuticals focuses on developing, manufacturing, and marketing high-quality pharmaceutical products, including those for unmet medical needs.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has received FDA approval for its Nitrofurantoin Oral Suspension (25 mg/5 ml), a generic version of Furadantin®, addressing a market worth approximately $55.5 million annually. This approval aligns with ANI's strategy to expand its generics portfolio by providing limited-competition products to benefit patient populations in need. CEO Nikhil Lalwani emphasized the company's commitment to launching new products as a priority for growth.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has received FDA approval for its Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g, a generic version of Colestid®.
This market is valued at approximately $81.3 million annually in the U.S., according to IQVIA/IMS Health. CEO Nikhil Lalwani noted the launch expands their generics portfolio, emphasizing the limited suppliers for this product.
ANI aims to enhance its growth through access to high-quality medicines and strengthening its generics business.
ANI Pharmaceuticals (ANIP) reported a strong performance in Q4 2022, achieving net revenues of $94.2 million—a 54.7% increase year-over-year. However, the company incurred a net loss of $(4.7) million, translating to a diluted GAAP loss per share of $(0.28). For full-year 2022, total net revenues reached $316.4 million, alongside a net loss of $(49.5) million. The company anticipates 2023 net revenue guidance of $360 million to $385 million, with adjusted EBITDA expected between $78 million and $88 million. ANI is focusing on its Rare Disease segment, particularly the Cortrophin Gel, and projects substantial revenue growth in this area.
Cosette Pharmaceuticals has announced the acquisition of US marketing rights for Betaine Anhydrous for Oral Solution from ANI Pharmaceuticals (ANIP), beginning immediate shipping to customers. This product provides an important treatment option for patients suffering from homocystinuria, a rare genetic disorder. The CEO of Cosette, Apurva Saraf, emphasized that this launch reflects the company's commitment to innovation and partnership in the pharmaceutical industry. The initiative aims to support U.S. patients and healthcare providers with a safe and effective medication.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will announce its fourth quarter and full year 2022 financial results on March 9, 2023, before the market opens. The call will include insights from Nikhil Lalwani, CEO, and Stephen P. Carey, CFO, at 8:30 a.m. ET. Interested parties can participate via a conference call at 800-343-5172 or through a webcast available on the ANI website. Following the call, a replay will be accessible for two weeks. ANI Pharmaceuticals focuses on developing high-quality branded and generic pharmaceuticals, particularly in addressing high unmet medical needs.